Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome

Steve Norris, Joseph Wheat, Dave McKinsey, Dan Lancaster, Barry Katz, John Black, Michael Driks, Robert Baker, Karen Israel, Don Traeger, Susan Moriarity, Joe Fraiz, Douglas Webb, Thomas Slama

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

objective: To assess the effectiveness of fluconazole for suppression of relapse of histoplasmosis in patients with acquired immunodeficiency syndrome (AIDS). design: Retrospective, nonrandomized, open trial. setting: Multicenter at two university referral centers and in five private practices. patients: Seventy-six patients with AIDS and disseminated histoplasmosis who completed induction treatment with amphotericin B, itraconazole, or fluconazole and maintained on treatment with fluconazole to prevent relapse. interventions: Fluconazole was given at dosages of 100 to 400 mg per day. Patients were followed by their primary physicians, who completed questionnaires collecting information about treatment and relapse status. Blood and urine specimens were submitted periodically for Histoplasma capsulatum var. capsulatum antigen determination. measurements and main results: Nine of the 76 patients relapsed during fluconazole therapy and another was removed from the study because of allergic rash. Survival after initiation of therapy for histoplasmosis was 94 weeks, ranging from 74 weeks for those who received less than 1 g of amphotericin B for induction and none for maintenance therapy to 156 weeks for those who received greater than 1 g for induction and additional amphotericin B for maintenance therapy before beginning fluconazole (P < 0.02). Antigen levels fell at rates of 0.05 units/week in urine and 0.02 units/week in serum in patients who were successfully maintained in remission and increased by ≥2 units/week in 4 of 6 patients who relapsed. conclusions: Fluconazole ≥200 mg daily is a reasonable choice for chronic suppressive therapy of histoplasmosis in patients who cannot take itraconazole because of drug interactions, malabsorption, or side effects.

Original languageEnglish
Pages (from-to)504-508
Number of pages5
JournalThe American Journal of Medicine
Volume96
Issue number6
DOIs
StatePublished - 1994

Fingerprint

Histoplasmosis
Fluconazole
Secondary Prevention
Acquired Immunodeficiency Syndrome
Amphotericin B
Itraconazole
Therapeutics
Recurrence
Urine
Histoplasma
Antigens
Private Practice
Exanthema
Drug Interactions
Referral and Consultation
Physicians
Survival

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. / Norris, Steve; Wheat, Joseph; McKinsey, Dave; Lancaster, Dan; Katz, Barry; Black, John; Driks, Michael; Baker, Robert; Israel, Karen; Traeger, Don; Moriarity, Susan; Fraiz, Joe; Webb, Douglas; Slama, Thomas.

In: The American Journal of Medicine, Vol. 96, No. 6, 1994, p. 504-508.

Research output: Contribution to journalArticle

Norris, S, Wheat, J, McKinsey, D, Lancaster, D, Katz, B, Black, J, Driks, M, Baker, R, Israel, K, Traeger, D, Moriarity, S, Fraiz, J, Webb, D & Slama, T 1994, 'Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome', The American Journal of Medicine, vol. 96, no. 6, pp. 504-508. https://doi.org/10.1016/0002-9343(94)90089-2
Norris, Steve ; Wheat, Joseph ; McKinsey, Dave ; Lancaster, Dan ; Katz, Barry ; Black, John ; Driks, Michael ; Baker, Robert ; Israel, Karen ; Traeger, Don ; Moriarity, Susan ; Fraiz, Joe ; Webb, Douglas ; Slama, Thomas. / Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. In: The American Journal of Medicine. 1994 ; Vol. 96, No. 6. pp. 504-508.
@article{794e4cc6c73f4b489b7927a50c308d63,
title = "Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome",
abstract = "objective: To assess the effectiveness of fluconazole for suppression of relapse of histoplasmosis in patients with acquired immunodeficiency syndrome (AIDS). design: Retrospective, nonrandomized, open trial. setting: Multicenter at two university referral centers and in five private practices. patients: Seventy-six patients with AIDS and disseminated histoplasmosis who completed induction treatment with amphotericin B, itraconazole, or fluconazole and maintained on treatment with fluconazole to prevent relapse. interventions: Fluconazole was given at dosages of 100 to 400 mg per day. Patients were followed by their primary physicians, who completed questionnaires collecting information about treatment and relapse status. Blood and urine specimens were submitted periodically for Histoplasma capsulatum var. capsulatum antigen determination. measurements and main results: Nine of the 76 patients relapsed during fluconazole therapy and another was removed from the study because of allergic rash. Survival after initiation of therapy for histoplasmosis was 94 weeks, ranging from 74 weeks for those who received less than 1 g of amphotericin B for induction and none for maintenance therapy to 156 weeks for those who received greater than 1 g for induction and additional amphotericin B for maintenance therapy before beginning fluconazole (P < 0.02). Antigen levels fell at rates of 0.05 units/week in urine and 0.02 units/week in serum in patients who were successfully maintained in remission and increased by ≥2 units/week in 4 of 6 patients who relapsed. conclusions: Fluconazole ≥200 mg daily is a reasonable choice for chronic suppressive therapy of histoplasmosis in patients who cannot take itraconazole because of drug interactions, malabsorption, or side effects.",
author = "Steve Norris and Joseph Wheat and Dave McKinsey and Dan Lancaster and Barry Katz and John Black and Michael Driks and Robert Baker and Karen Israel and Don Traeger and Susan Moriarity and Joe Fraiz and Douglas Webb and Thomas Slama",
year = "1994",
doi = "10.1016/0002-9343(94)90089-2",
language = "English",
volume = "96",
pages = "504--508",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome

AU - Norris, Steve

AU - Wheat, Joseph

AU - McKinsey, Dave

AU - Lancaster, Dan

AU - Katz, Barry

AU - Black, John

AU - Driks, Michael

AU - Baker, Robert

AU - Israel, Karen

AU - Traeger, Don

AU - Moriarity, Susan

AU - Fraiz, Joe

AU - Webb, Douglas

AU - Slama, Thomas

PY - 1994

Y1 - 1994

N2 - objective: To assess the effectiveness of fluconazole for suppression of relapse of histoplasmosis in patients with acquired immunodeficiency syndrome (AIDS). design: Retrospective, nonrandomized, open trial. setting: Multicenter at two university referral centers and in five private practices. patients: Seventy-six patients with AIDS and disseminated histoplasmosis who completed induction treatment with amphotericin B, itraconazole, or fluconazole and maintained on treatment with fluconazole to prevent relapse. interventions: Fluconazole was given at dosages of 100 to 400 mg per day. Patients were followed by their primary physicians, who completed questionnaires collecting information about treatment and relapse status. Blood and urine specimens were submitted periodically for Histoplasma capsulatum var. capsulatum antigen determination. measurements and main results: Nine of the 76 patients relapsed during fluconazole therapy and another was removed from the study because of allergic rash. Survival after initiation of therapy for histoplasmosis was 94 weeks, ranging from 74 weeks for those who received less than 1 g of amphotericin B for induction and none for maintenance therapy to 156 weeks for those who received greater than 1 g for induction and additional amphotericin B for maintenance therapy before beginning fluconazole (P < 0.02). Antigen levels fell at rates of 0.05 units/week in urine and 0.02 units/week in serum in patients who were successfully maintained in remission and increased by ≥2 units/week in 4 of 6 patients who relapsed. conclusions: Fluconazole ≥200 mg daily is a reasonable choice for chronic suppressive therapy of histoplasmosis in patients who cannot take itraconazole because of drug interactions, malabsorption, or side effects.

AB - objective: To assess the effectiveness of fluconazole for suppression of relapse of histoplasmosis in patients with acquired immunodeficiency syndrome (AIDS). design: Retrospective, nonrandomized, open trial. setting: Multicenter at two university referral centers and in five private practices. patients: Seventy-six patients with AIDS and disseminated histoplasmosis who completed induction treatment with amphotericin B, itraconazole, or fluconazole and maintained on treatment with fluconazole to prevent relapse. interventions: Fluconazole was given at dosages of 100 to 400 mg per day. Patients were followed by their primary physicians, who completed questionnaires collecting information about treatment and relapse status. Blood and urine specimens were submitted periodically for Histoplasma capsulatum var. capsulatum antigen determination. measurements and main results: Nine of the 76 patients relapsed during fluconazole therapy and another was removed from the study because of allergic rash. Survival after initiation of therapy for histoplasmosis was 94 weeks, ranging from 74 weeks for those who received less than 1 g of amphotericin B for induction and none for maintenance therapy to 156 weeks for those who received greater than 1 g for induction and additional amphotericin B for maintenance therapy before beginning fluconazole (P < 0.02). Antigen levels fell at rates of 0.05 units/week in urine and 0.02 units/week in serum in patients who were successfully maintained in remission and increased by ≥2 units/week in 4 of 6 patients who relapsed. conclusions: Fluconazole ≥200 mg daily is a reasonable choice for chronic suppressive therapy of histoplasmosis in patients who cannot take itraconazole because of drug interactions, malabsorption, or side effects.

UR - http://www.scopus.com/inward/record.url?scp=0028232795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028232795&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(94)90089-2

DO - 10.1016/0002-9343(94)90089-2

M3 - Article

C2 - 8017447

AN - SCOPUS:0028232795

VL - 96

SP - 504

EP - 508

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -